Abstracts tagged "Bone density"

Abstract Number: 4 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA)-Related Joint Symptoms and Thoracic Bone Mineral Density in an RA-Free Community Dwelling Population
Jan M. Hughes-Austin¹, Joachim H. Ix², Samuel R. Ward³, M. Kristen Demoruelle⁴, V. Michael Holers⁵, Jill M. Norris⁶ and Kevin D. Deane⁷, ¹Orthopaedic Surgery, University of California, San Diego, La Jolla, CA, ²University of California, San Diego, La Jolla, CA, ³Radiology, Orthopaedic Surgery, and Bioengineering, University of California, San Diego, La Jolla, CA, ⁴1775 Aurora Ct, 1775 Aurora Ct, Aurora, CO, ⁵Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁶University of Colorado Denver, Aurora, CO, ⁷Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Osteoporosis, defined by Tscore < -2.5, is one of the main consequences of RA and it appears early in the disease. It is twice…
Abstract Number: 167 • 2016 ACR/ARHP Annual Meeting
Bone Mineral Density Loss in Clinically Suspect Arthralgia Is Associated with Subclinical Inflammation and Progression to Clinical Arthritis
L. Mangnus¹, H.W. van Steenbergen², M. Reijnierse³, J. Kälvesten^4,5,6 and A.H.M. van der Helm-van Mil², ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Radiology, Faculty of Health Sciences, Linköping, Sweden, ⁵Center for Medical Image Science and Visualization, Linköping University, Linköping, Sweden, ⁶Sectra AB, Linköping, Sweden
Background/Purpose: Peripheral bone mineral density (BMD) can be decreased in early rheumatoid arthritis but it is unknown if BMD loss emerges already before arthritis is…
Abstract Number: 321 • 2016 ACR/ARHP Annual Meeting
Results of a Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Romosozumab in Men with Osteoporosis
EM Lewiecki¹, S Horlait², T Blicharski³, S Goemaere⁴, K Lippuner⁵, P Meisner⁶, PD Miller⁷, A Miyauchi⁸, J Maddox⁹, NS Daizadeh⁹ and A Grauer⁹, ¹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ²Amgen Ltd., Uxbridge, United Kingdom, ³Medical University of Lublin, Lublin, Poland, ⁴Ghent University Hospital, Gent, Belgium, ⁵Bern University Hospital, Bern, Switzerland, ⁶UCB Pharma, Brussels, Belgium, ⁷Colorado Center for Bone Research, Lakewood, CO, ⁸Miyauchi Medical Center, Osaka, Japan, ⁹Amgen Inc., Thousand Oaks, CA
Background/Purpose: Treatment with romosozumab (Romo) has been shown to rapidly increase BMD in postmenopausal women with low BMD through a dual effect on bone, increasing…
Abstract Number: 343 • 2016 ACR/ARHP Annual Meeting
Correlation Between Metacarpal Cortical Bone Mineral Density Measured By Dual X-Ray Densitometry and Radiogrammetry on Early Arthritis Patients
Irene Llorente Cubas*¹, Leticia Merino-Meléndez², Ana M. Ortiz Garcia³, Saturnino González Ortega⁴, Eugenio Escolano⁵, Alberto Garcia-Vadillo⁶, Esther Vicente-Rabaneda², Rosario Garcia-Vicuña⁶, Isidoro Gonzalez-Alvaro³ and Santos Castañeda⁷, ¹Rheumatology, H.U La Princesa, Madrid, Spain, ²Rheumatology, H.U. La Princesa, Madrid, Spain, ³Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁴X-ray diagnosis, X-ray diagnosis, Hospital de La Princesa, Madrid, Spain, ⁵Radiology Department, H.U La Princesa, Madrid, Spain, ⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁷Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain
Background/Purpose: Low bone mass at metacarpal (MC) diaphysis measured by radiogrammetry (DXR) has been described as a poor prognostic factor in rheumatoid arthritis (RA). However,…
Abstract Number: 350 • 2016 ACR/ARHP Annual Meeting
Change in Bone Mineral Density with High-Dose Prednisone in Patients with Rheumatoid Arthritis
Linda Rasch¹, Lilian van Tuyl¹, Martijn Kremer², Irene E.M. Bultink², Maarten Boers^3,4 and Willem F. Lems^1,4, ¹Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: Recently, we showed that treatment with COBRA-light therapy including prednisone with initially 30 mg/day, was as effective as the original COBRA scheme, with initially…
Abstract Number: 359 • 2016 ACR/ARHP Annual Meeting
The Association of Scheuermann’s Disease with Osteoporotic Vertebral Fracture Risk
Marine Gaudé¹, R Chapurlat² and Pawel Szulc³, ¹Rheumatology, INSERM UMR 1033 and University of Lyon, Hôpital Edouard Herriot, Lyon, France, ²INSERM UMR 1033 and University of Lyon, Hôpital Edouard Herriot, Lyon, France, ³Epidemiology of Osteoporosis, INSERM UMR 1033, Lyon, France
Background/Purpose: Scheuermann’s disease is one of the most frequent illnesses of the spine in teenagers. Its evolution over time is poorly understood. Spinal deformities, by…
Abstract Number: 344 • 2015 ACR/ARHP Annual Meeting
Results of a Phase 2 Clinical Trial to Evaluate the Effects of Romosozumab in Japanese Women with Postmenopausal Osteoporosis
H Ishibashi¹, DB Crittenden², A Miyauchi³, C Libanati⁴, J Maddox², L Chen² and A Grauer², ¹Ina Hospital, Saitama, Japan, ²Amgen Inc., Thousand Oaks, CA, ³Miyauchi Medical Center, Osaka, Japan, ⁴UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab is a sclerostin inhibitor that rapidly increases bone mineral density (BMD) through a dual effect on bone, causing increased bone formation and decreased…
Abstract Number: 352 • 2015 ACR/ARHP Annual Meeting
Low Bone Density Is Associated with Atherosclerotic Disease in Patients with Psoriatic Arthritis
Eirik Ikdahl^1,2, Hege Kilander Høiberg³, Silvia Rollefstad², Andreas P Diamantopoulos^4,5, Grunde Wibetoe², Arthur Kavanaugh⁶, Inge C Olsen⁷, Tore K. Kvien⁷, Anne Grete Semb⁸ and Glenn Haugeberg⁹, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁴Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ⁵Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁶University of California San Diego, La Jolla, CA, ⁷Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Diakonhjemmet Hospital, Oslo, Norway, ⁹Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: There is an evidence vacuum concerning the mechanisms underlying the high atherosclerotic cardiovascular disease (ASCVD) burden in patients with psoriatic arthritis (PsA). In the…
Abstract Number: 376 • 2015 ACR/ARHP Annual Meeting
The Relationships Between Bone Mineral Density and Radiographic Features of Hand or Knee Osteoarthritis in Older Adults: Data from the Dong-Gu Study
Kyung-Eun Lee¹, Lihui Wen¹, Yi-Rang Yim¹, Ji-Eun Kim¹, Jeong-Won Lee¹, Dong-Jin Park², Shin-Seok Lee¹ and Shin-Seok Lee's group, ¹Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea
Background/Purpose: The relationship between osteoarthritis (OA) and osteoporosis has exhibited contradictory features over the past four decades. We evaluated this relationship using separate analysis of…
Abstract Number: 579 • 2015 ACR/ARHP Annual Meeting
Methotrexate Does Not Influence 1-Year Bone Mineral Density in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Richard Koch¹, Thomas Barnetche², Adeline Ruyssen-Witrand¹, Alain Cantagrel¹, Arnaud Constantin³ and Yannick Degboé⁴, ¹Rheumatology Center, Purpan University Hospital, Toulouse, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Inserm U558, Rheumatology Center, Purpan University Hospital, Toulouse, France, ⁴Rheumatology, Rheumatology Center, Purpan University Hospital, Toulouse, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with reduction of bone mineral density (BMD) and increased risk of peripheral and axial fractures. Methotrexate is the first-line…
Abstract Number: 1317 • 2015 ACR/ARHP Annual Meeting
Clinical Utility of Joint Space Width and X-Ray Radiogrammetry in RA: Markers for Early Radiographic Progression
Michael Platten¹, Yogan Kisten², Johan Kälvesten³, Kristina Forslind⁴ and Ronald F. van Vollenhoven⁵, ¹Medicine, Karolinska Institutet, Huddinge, Sweden, ²ClinTRID, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Sectra AB, Stockholm, Sweden, ⁴Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ⁵Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Early prediction of radiographic progression is beneficial in rheumatoid arthritis (RA) patient management. The van der Heijde modified Sharp score (SHS) is currently the…
Abstract Number: 1706 • 2015 ACR/ARHP Annual Meeting
Prevalence and Factors Associated with Non-Traumatic Vertebral Fractures in Psoriatic Arthritis
Shelly Chandran¹, Sindhu R. Johnson², Angela Cheung³, David Salonen⁴ and Dafna Gladman⁵, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dept of Rheumatology, Toronto Western and Mt. Sinai Hospitals, University of Toronto, Toronto, ON, Canada, ³Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁴Department of Medical Imaging, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The prevalence of osteoporotic vertebral fractures (VF) in psoriatic arthritis (PsA) is not known. We aim to determine the prevalence and factors associated with…
Abstract Number: 2831 • 2014 ACR/ARHP Annual Meeting
Development of New Radiographic Vertebral Fractures in Patients with Ankylosing Spondylitis during 4 Years of TNF-α Blocking Therapy: Results from the Glas Cohort
Fiona Maas¹, Anneke Spoorenberg^1,2, Elisabeth Brouwer³, Reinhard Bos², Rizwana N. Chaudhry¹, Freke Wink², Hendrika Bootsma⁴, Eveline van der Veer⁵ and Suzanne Arends^2,4, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ³Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Previous studies have shown that the risk of vertebral fractures is increased in patients with ankylosing spondylitis (AS). Prospective longitudinal data about radiographic vertebral…
Abstract Number: 225 • 2014 ACR/ARHP Annual Meeting
Association Between Lean Mass and Hip Bone Mineral Density
Charlotte Beaudart¹, Jean-Yves Reginster², Justine Slomian³, Fanny Buckinx⁴ and Olivier Bruyere⁵, ¹Avenue De L'Hopital 3, University of Liège, Liège, Belgium, ²Bone Cartilage Unit, University of Liège, Liège, Belgium, ³Support Unit in Epidemiology and Biostatistics, University of Liège, Liège, Belgium, ⁴Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ⁵Public Health/Epidemiology, University of Liège, Liège, Belgium
Background/Purpose: Fat mass and lean mass (LM) represent 95% of body weight. However, the role of each component on bone mineral density (BMD) is not…
Abstract Number: 2558 • 2014 ACR/ARHP Annual Meeting
Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures
M.a.C. van der Weijden^1,2, J.C. van Denderen², W.F. Lems¹, M.T. Nurmohamed^1,2, B.a.C Dijkmans^1,2 and I.E. van der Horst-Bruinsma¹, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose Ankylosing spondylitis (AS) is characterized by chronic inflammation often leading to ankylosis of the spine, but also by a decrease of bone mineral density…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].